Akèy › Kansè Endomèt › Oklahoma › Oklahoma City
Etid klinik pou Kansè Endomèt nan Oklahoma City, OK
25 etid pou Kansè Endomèt ap chèche patisipan nan sit nan ak bò kote Oklahoma City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Ap rekriteFaz 1
- University of Oklahoma Health Sciences Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- University of Oklahoma, Oklahoma City
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Ap rekriteFaz 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Ap rekriteFaz 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of AVZO-021 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Ap rekriteFaz 1/2
- Stephenson Cancer Center, Oklahoma City
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Ap rekriteFaz 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- University of Oklahoma, Oklahoma City
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Ap rekriteFaz 3
- Peggy & Charles Stephenson Oklahoma Cancer Center, Oklahoma City
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Ap rekriteFaz 3
- Research Site, Oklahoma City
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Ap rekriteFaz 1
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Ap rekriteFaz 2
- Stephenson Cancer Center at OU Health, Oklahoma City
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ap rekriteFaz 1
- Normunity Investigational Site, Oklahoma City
A Study of DM002 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- University of Oklahoma - Health Sciences Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Stephenson Cancer Center, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Ap rekriteEtid obsèvasyon
- Mercy Hospital - OKC, Oklahoma City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Ap rekriteFaz 1/2
- University of Oklahoma Health Stephenson Cancer Center, Oklahoma City
Uterine Preservation Via Lifestyle Transformation
Ap rekriteFaz 2
- University of Oklahoma, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, Oklahoma City
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Ap rekriteFaz 1
- University of Oklahoma, Oklahoma City
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Ap rekriteFaz 2
- Oklahoma University Stephenson Cancer Center, Oklahoma City
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Ap rekriteFaz 2
- University of Oklahoma, Oklahoma City
Etid Kansè Endomèt nan lòt vil
- Houston, TX68 etid
- New York City, NY52 etid
- Boston, MA50 etid
- Arlington, VA39 etid
- Nashville, TN38 etid
- Los Angeles, CA34 etid
- St. Louis, MO29 etid
- Philadelphia, PA28 etid
- San Antonio, TX27 etid
- Chicago, IL25 etid
- Columbus, OH25 etid
- Queens, NY25 etid
Lòt etid nan Oklahoma City
- Kansè Poumon ki pa ti selil28 etid
- Kansè ovè28 etid
- Kansè kolorektal22 etid
- Kansè pwostat21 etid
- Kansè poumon19 etid
- Kansè nan tete17 etid
- Kansè Metastatik15 etid
- Kansè (tout kalite)14 etid
- Leksemi mieloïd egi14 etid
- Karsinòm selil skuamèz tèt ak kou13 etid
- Kansè pankreyas11 etid
- Kansè vejik11 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.